UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1458-1
Program Prior Authorization/Notification
Medication *Zymfentra (infliximab-dyyb)
*Zymfentra is excluded from coverage for the majority of our benefits
P&T Approval Date 10/2024
Effective Date 1/1/2025
1. Background:
Zymfentra (infliximab-dyyb) is a tumor necrosis factor (TNF) blocker indicated in adults for
maintenance treatment of moderately to severely active ulcerative colitis following treatment
with an infliximab product administered intravenously and moderately to severely active
Crohn’s disease following treatment with an infliximab product administered intravenously.
2. Coverage Criteriaa:
A. Ulcerative Colitis
1. Initial Authorization
a. Zymfentra* will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) Patient is not receiving Zymfentra in combination with a targeted
immunomodulator [e.g., adalimumab, Entyvio (vedolizumab), Olumiant
(baricitinib), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi
(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz
(tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Zymfentra* will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Zymfentra therapy
-AND-
(2) Patient is not receiving Zymfentra in combination with a targeted
immunomodulator [e.g., adalimumab, Entyvio (vedolizumab), Olumiant
(baricitinib), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi
(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz
© 2024 UnitedHealthcare Services, Inc.
1
(tofacitinib)]
Authorization will be issued for 12 months.
B. Crohn’s Disease
1. Initial Authorization
a. Zymfentra* will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) Patient is not receiving Zymfentra in combination with a targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia
(abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi
(risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Zymfentra* will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Zymfentra therapy
-AND-
(2) Patient is not receiving Zymfentra in combination with a targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia
(abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi
(risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Exclusion: Zymfentra is excluded from coverage for the majority of our benefits
• Supply limits and/or Medical Necessity may be in place.
© 2024 UnitedHealthcare Services, Inc.
2
4. References:
1. Zymfentra [package insert]. Jersey City, NJ: Celltrion USA, Inc.; February 2024.
Program Prior Authorization/Notification – Zymfentra (infliximab-dyyb)
Change Control
10/2024 New program.
© 2024 UnitedHealthcare Services, Inc.
3